Evidence map›Paper›PMID 34866371›Full record

ArticleJournal of clinical research in pediatric endocrinology2022

A 4-hour Profile of 17-hydroxyprogesterone in Salt-wasting Congenital Adrenal Hyperplasia: Is the Serial Monitoring Strategy Worth the Effort?

Özge Besci, İbrahim Mert Erbaş, Tuncay Küme, Kübra Yüksek Acinikli, Ayhan Abacı, Ece Böber, Korcan Demir

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical research in pediatric endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Özge BesciDokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, TurkeyORCID 0000-0003-3135-9617
İbrahim Mert ErbaşDokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, TurkeyORCID 0000-0001-9368-8868
Tuncay KümeDokuz Eylül University Faculty of Medicine, Department of Medical Biochemistry, İzmir, TurkeyORCID 0000-0003-3440-3513
Kübra Yüksek AcinikliDokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, TurkeyORCID 0000-0001-9492-4834
Ayhan AbacıDokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, TurkeyORCID 0000-0002-1812-0321
Ece BöberDokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, TurkeyORCID 0000-0001-8828-0892
Korcan DemirDokuz Eylül University Faculty of Medicine, Department of Pediatric Endocrinology, İzmir, TurkeyORCID 0000-0002-8334-2422
Dokuz Eylül University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Since there is no gold standard laboratory variable for adjustment of treatment in congenital adrenal hyperplasia (CAH), the aim was to assess the use of a 4-hour profile of serum 17-hydroxyprogesterone (17-OHP) to determine the most appropriate sample time and level of 17-OHP in predicting the metabolic control and evaluate the role of sex hormone-binding globulin (SHBG) in hyperandrogenemia. Methods: This study included children with salt-wasting CAH. Measurements for 17-OHP and cortisol were made from samples obtained before and 1, 2, and 4 hours after the morning dose of hydrocortisone. Patients were designated to have poor metabolic control when androstenedione levels according to age and sex-specific reference intervals were high and annual height standard deviation score (SDS) changes were ≥0.5. Results: The study cohort was 16 children (9 girls) with a median age of 7-years old. Premedication 17-OHP levels were strongly correlated with 17-OHP levels 1, 2, and 4 hours after the morning dose (r Conclusion: We conclude that: (i) a 4-hour 17-OHP profile is not useful in predicting hyperandrogenemia; (ii) suppressed levels of 17-OHP do not always indicate overtreatment; (iii) reference intervals of 17-OHP for different time periods might be of importance; (iv) low hydrocortisone doses should be avoided; and (v) SHBG could be used in pubertal children as an indicator of hyperandrogenemia.

Indexed as

Adrenal Hyperplasia, CongenitalUrogenital Abnormalities17-alpha-HydroxyprogesteroneAndrogensAndrostenedioneBody HeightChildFemaleHumansHydrocortisoneMale17-alpha-HydroxyprogesteroneAndrogensAndrostenedioneHydrocortisoneadrenocorticotropic hormoneandrogensCYP21A2steroid

Identifiers

PMID34866371
PMCPMC9176089
OpenAlexW4200443786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.